ATE266396T1 - Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese - Google Patents

Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese

Info

Publication number
ATE266396T1
ATE266396T1 AT99955613T AT99955613T ATE266396T1 AT E266396 T1 ATE266396 T1 AT E266396T1 AT 99955613 T AT99955613 T AT 99955613T AT 99955613 T AT99955613 T AT 99955613T AT E266396 T1 ATE266396 T1 AT E266396T1
Authority
AT
Austria
Prior art keywords
preparation
rar antagonists
promote chondrogenesis
chondrogenesis
promote
Prior art date
Application number
AT99955613T
Other languages
English (en)
Inventor
Tully Michael Underhill
Andrea Dawn Weston
Original Assignee
Univ Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario filed Critical Univ Western Ontario
Application granted granted Critical
Publication of ATE266396T1 publication Critical patent/ATE266396T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AT99955613T 1998-11-19 1999-11-19 Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese ATE266396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002254429A CA2254429A1 (en) 1998-11-19 1998-11-19 Compositions for promoting chondrogenesis
PCT/CA1999/001106 WO2000030635A1 (en) 1998-11-19 1999-11-19 Composition and use of rar antagonists for promoting chondrogenesis

Publications (1)

Publication Number Publication Date
ATE266396T1 true ATE266396T1 (de) 2004-05-15

Family

ID=4163043

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955613T ATE266396T1 (de) 1998-11-19 1999-11-19 Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese

Country Status (10)

Country Link
US (3) US7186418B1 (de)
EP (1) EP1131067B1 (de)
JP (1) JP2002530331A (de)
AT (1) ATE266396T1 (de)
AU (1) AU764394B2 (de)
CA (2) CA2254429A1 (de)
DE (1) DE69917317T2 (de)
ES (1) ES2219076T3 (de)
HK (1) HK1041633B (de)
WO (1) WO2000030635A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018885A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US20030114482A1 (en) * 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) * 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
WO2003024473A2 (en) * 2001-09-17 2003-03-27 The University Of Western Ontario Retinoid receptor pan-antagonists for stimulating chondrogenesis
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
CA2520445A1 (en) * 2003-03-25 2004-10-07 Japan Science And Technology Agency Induction of differentiation of stem cells, and control of differentiation potency of stem cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
DE102011007377A1 (de) * 2010-12-22 2012-06-28 Tridonic Gmbh & Co Kg LED-Lampen mit poröser Wärmesenke
DE102011013292A1 (de) 2011-03-08 2012-09-13 Rettig Icc B.V. Halter und Magazin aus Haltern zur Befestigung eines Rohres einer Fußbodenheizung sowie Setzgerät zur Verarbeitung eines derartigen Magazins
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
CN117679520A (zh) * 2022-09-09 2024-03-12 北京达尔文细胞生物科技有限公司 用于防治后遗症期面神经麻痹的药物组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US5354557A (en) * 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
FR2735371B1 (fr) 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes antagonistes des recepteurs rars
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
CA2263817A1 (en) * 1996-08-28 1998-03-05 Centre National De La Recherche Scientifique Therapeutic combinations of rar antagonists and rxr agonists and use thereof
JP4005160B2 (ja) 1996-10-11 2007-11-07 紘一 首藤 レチノイドアンタゴニスト
EP0977892A1 (de) * 1997-04-24 2000-02-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methoden und zusammensetzungen zur regulation der expresssion von matrix-metalloproteinase genen
EP0896825B1 (de) * 1997-08-14 2002-07-17 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
WO1999024415A1 (en) * 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Retinoid receptor agonists
US6326397B1 (en) * 1998-11-10 2001-12-04 Hoffman-La Roche Inc. Retinoid antagonists and use thereof

Also Published As

Publication number Publication date
US20100003307A1 (en) 2010-01-07
DE69917317D1 (de) 2004-06-17
EP1131067A1 (de) 2001-09-12
ES2219076T3 (es) 2004-11-16
EP1131067B1 (de) 2004-05-12
CA2254429A1 (en) 2000-05-19
HK1041633A1 (en) 2002-07-19
US20070134198A1 (en) 2007-06-14
AU764394B2 (en) 2003-08-14
CA2349555A1 (en) 2000-06-02
HK1041633B (en) 2004-10-08
US7186418B1 (en) 2007-03-06
JP2002530331A (ja) 2002-09-17
DE69917317T2 (de) 2005-07-28
WO2000030635A1 (en) 2000-06-02
AU1255200A (en) 2000-06-13
US7608281B2 (en) 2009-10-27

Similar Documents

Publication Publication Date Title
DE69917317D1 (de) Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
DE60214477D1 (de) Implantat zur Regeneration von Knorpelgewebe
YU7797A (sh) Kombinovana terapija za osteoporozu
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
AR023130A1 (es) Composiciones para promover el crecimiento
MXPA04001334A (es) Materiales y metodos para promover la reparacion de tejido nervioso.
PT881908E (pt) Utilizacao dos factores de crescimento de fibroblasto para estimular o crescimento osseo
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE369077T1 (de) Wiederherstellung von beschädigtem gewebe
SG148037A1 (en) Fgf variants and methods for use thereof
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE268144T1 (de) Repositionsinstrument zur fixation von knochenfrakturen
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
ID28460A (id) Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
AU5548801A (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer&#39;s krankheit
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties